Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T Li,Funda Meric-Bernstam,Aditya Bardia,Yoichi Naito,Salvatore Siena,Philippe Aftimos,Ian Anderson,Giuseppe Curigliano,Maria de Miguel,Maitri Kalra,Do-Youn Oh,Joon Oh Park,Sophie Postel-Vinay,Sun Young Rha,Taroh Satoh,Iben Spanggaard,Flavia Michelini,Ann Smith,Karime Kalil Machado,Cristina Saura,Bob T Li,Funda Meric-Bernstam,Aditya Bardia,Yoichi Naito,Salvatore Siena,Philippe Aftimos,Ian Anderson,Giuseppe Curigliano,Maria de Miguel,Maitri Kalra,Do-Youn Oh,Joon Oh Park,Sophie Postel-Vinay,Sun Young Rha,Taroh Satoh,Iben Spanggaard,Flavia Michelini,Ann Smith,Karime Kalil Machado,Cristina Saura
DOI: https://doi.org/10.1016/s1470-2045(24)00140-2
IF: 54.433
2024-05-06
The Lancet Oncology
Abstract:Summary Background Trastuzumab deruxtecan is a HER2-directed antibody–drug conjugate approved by the US Food and Drug Administration and the European Medicines Agency for HER2 -mutant non-small-cell lung cancer. Few treatment options exist for patients with HER2 -mutant solid tumours beyond lung cancers. We investigated trastuzumab deruxtecan in metastatic solid tumours with specific activating HER2 mutations. Methods In this open-label, phase 2, basket study done in 29 centres in Asia, Europe, and North America, we investigated trastuzumab deruxtecan (5·4 mg/kg every 3 weeks by intravenous infusion) in patients aged 18 years or older with unresectable or metastatic solid tumours with specific activating HER2 mutations, an Eastern Cooperative Oncology Group performance status of 0 or 1, and disease progression following previous treatment (previous HER2-targeted therapy was permitted) or with no satisfactory alternative treatment options. The primary endpoint was confirmed objective response rate by independent central review. Anti-tumour activity and safety were analysed in all patients who received at least one dose of trastuzumab deruxtecan. This trial is registered with ClinicalTrials.gov , NCT04639219 , and is active but no longer recruiting. Findings Between Dec 30, 2020, and Jan 25, 2023, 102 patients (62 [61%] female and 40 [39%] male; median age 66·5 years [IQR 58–72]; 51 [50%] White, two [2%] Black or African American, 38 [37%] Asian, and 11 [11%] did not have race information reported) with solid tumours with activating HER2 mutations received trastuzumab deruxtecan and were included in the anti-tumour activity and safety analyses sets. Patients had a median of three (IQR 2–4) previous treatment regimens. The median duration of follow-up was 8·61 months (IQR 3·71–12·68). The objective response rate by independent central review was 29·4% (95% CI 20·8–39·3; 30 of 102 patients). 52 (51%) patients had a treatment-emergent adverse event of grade 3 or worse; the most common events (in ≥5% of patients) were anaemia (16 [16%]) and neutrophil count decreased (eight [8%]). Drug-related treatment-emergent serious adverse events occurred in ten (10%) patients. Adjudicated drug-related interstitial lung disease or pneumonitis of any grade occurred in 11 patients (11%; three grade 1, five grade 2, one grade 3, and two grade 5); there were two (2%) cases of fatal adjudicated drug-related interstitial lung disease or pneumonitis. Interpretation Trastuzumab deruxtecan showed anti-tumour activity and durable responses in heavily pretreated patients across multiple tumour types with activating HER2 mutations, with no new safety signals. Prespecified HER2 mutations might be targeted by HER2-directed antibody–drug conjugates and our findings support further investigation of trastuzumab deruxtecan in the pan-tumour setting. Funding AstraZeneca and Daiichi Sankyo.
oncology